Search

Takeda Pharmaceutical Co Ltd ADR

Cerrado

SectorSanidad

20.87 -0.29

Resumen

Variación precio

24h

Actual

Mínimo

20.89

Máximo

20.93

Métricas clave

By Trading Economics

Ingresos

138B

113B

Ventas

105B

1.2T

P/B

Media del Sector

42.622

50.373

BPA

0.48

Rentabilidad por dividendo

3.05

Margen de beneficios

9.279

Empleados

47,029

EBITDA

231B

389B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+106.37% upside

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

3.05%

2.12%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

9.6B

65B

Apertura anterior

21.16

Cierre anterior

20.87

Takeda Pharmaceutical Co Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2026, 13:01 UTC

News

Michael Saylor plans to purchase additional Bitcoin, aiming to exceed 850k BTC for the first time.

31 oct 2026, 00:02 UTC

News

Lyft, Inc. shares are advancing in after-market trading, supported by a broader market uptick.

31 oct 2026, 00:02 UTC

Social Media
Correlated Moves
News

MSCI Inc. will continue using regular trading hours closing prices for index calculations, despite updates on trading extensions from Nasdaq and NYSE Arca.

31 oct 2026, 00:02 UTC

Correlated Moves
News

Cantor Fitzgerald identifies buying opportunity in crypto-linked stocks, including Strategy Inc, following Binance hack, noting potential for recovery as panic subsides.

31 oct 2026, 00:02 UTC

Correlated Moves
News

Allegro Microsystems Inc reported Q2 FY27 sales of $276.88 million and net income of $23.26 million, with shares trading higher in after-market hours.

31 oct 2026, 00:02 UTC

News

Okta, Inc. will replace Kenvue in the S&P 500 on November 4, 2026, following Kimberly-Clark's acquisition, enhancing its visibility to investors.

31 oct 2026, 00:02 UTC

News

DICK'S Sporting Goods faces class action lawsuits alleging securities fraud and misleading investors about financial performance following an earnings miss.

31 oct 2026, 00:02 UTC

News
Social Media

Coinbase Global, Inc. saw an uptick in after-market trading after JP Morgan maintained its Overweight rating but lowered the price target to $187.

31 oct 2026, 00:01 UTC

News

Mondelez International, Inc. shares traded modestly lower during after-market hours on Friday, following a decline from a brief peak earlier in the session.

31 oct 2026, 00:01 UTC

News

Kimberly-Clark Corporation is set to acquire Kenvue, with the transaction expected to close soon, subject to final conditions.

31 oct 2026, 00:01 UTC

News

Kraft Heinz Company shares advanced in after-market trading, reaching their highest point since Friday's close and trading near the upper end of their one-month range.

31 oct 2026, 00:01 UTC

News

BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in its share price during after-market hours.

31 oct 2026, 00:01 UTC

News

Ares Capital Corporation announced a merger agreement to acquire MidCap Financial Investment Corporation, resulting in the cancellation of MidCap's earnings call on November 5, 2026.

31 oct 2026, 00:01 UTC

News

BWX Technologies Inc is rising in after-market trading after being selected by the U.S. Army to develop a nuclear microreactor for its $2.2 billion Janus program.

30 oct 2026, 23:51 UTC

News

FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.

30 oct 2026, 23:51 UTC

News

BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.

30 oct 2026, 23:51 UTC

News

Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.

30 oct 2026, 23:41 UTC

News

Allegro Microsystems Inc. reported Q2 FY27 sales of $276.88M, exceeding expectations, and provided Q3 guidance of $278M to $288M, with shares modestly higher in after-market trading.

30 oct 2026, 23:41 UTC

News

BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in the stock's price during after-market hours.

30 oct 2026, 23:36 UTC

News

Capri Holdings Ltd reported Q2 profit of 42 cents per share and raised full-year EPS forecast to $2.20, with shares trading lower in after-market hours.

30 oct 2026, 23:31 UTC

News

McGrath RentCorp will replace Glaukos in the S&P 600 index at the market open on November 4, 2026, contributing to positive after-market price movement.

30 oct 2026, 23:26 UTC

News

JP Morgan maintains its Underweight rating on T. Rowe Price while raising the price target to $107; TD Cowen lowers its target to $96.

30 oct 2026, 23:26 UTC

News

Citigroup reaffirms Buy rating on Fortrea Holdings Inc and raises price target to $27, according to a report published today.

30 oct 2026, 23:21 UTC

News

Compass Inc. faces a class action lawsuit from Pomerantz LLP, alleging securities fraud related to its merger with Anywhere Real Estate Inc.

30 oct 2026, 23:16 UTC

News

JP Morgan maintains Neutral rating on Dexcom Inc and raises its price target to $85, reflecting the company's market position and growth potential.

30 oct 2026, 23:11 UTC

News

Pomerantz LLP has filed a class action lawsuit against The Chemours Company, alleging misleading statements and violations of federal securities laws.

30 oct 2026, 23:11 UTC

News

Cantor Fitzgerald identifies Binance's $6.3 billion hack as a potential buying opportunity for crypto-linked stocks, including Strategy Inc., amid recovery confidence.

30 oct 2026, 23:06 UTC

News

Uranium Energy Corp. shares declined in after-market hours, reflecting broader sector pressures despite analysts noting tightening supply in the uranium market.

30 oct 2026, 23:06 UTC

News
Social Media

S&P Global Ratings revised its outlook on Meta Platforms, Inc. to negative, citing uncertainty over capital expenditures and projected free operating cash flow deficits.

30 oct 2026, 23:06 UTC

News
Social Media

eBay expands managed shipping program amid seller eligibility concerns.

Comparación entre iguales

Cambio de precio

Takeda Pharmaceutical Co Ltd ADR previsión

Precio Objetivo

By TipRanks

106.37% repunte

Estimación a 12 Meses

Media 43.153 USD  106.37%

Máximo 43.153 USD

Mínimo 43.153 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Takeda Pharmaceutical Co Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat